secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0001770787-24-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics appoints Sarah A. Teichmann to Board of Directors
--------------------------------------------------------------

- Effective July 10, 2024; Class II director with term expiring at 2027 annual meeting.
- Teichmann is Chair in Stem Cell Medicine at University of Cambridge and co-chair of Human Cell Atlas.
- She receives $55,000 annual cash retainer plus initial RSU grant valued at $400,000.
- Annual RSU grant of $215,000 on annual meeting date; both grants vest over time with continued service.
- Also serves as VP at GSK and CSO at EnsoCell Therapeutics; brings genomics and leadership expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000048/0001770787-24-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000048/txg-20240710.htm
  HTML page:      https://secwatch.observer/filing/0001770787-24-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer